Moderna, Inc.

NASDAQ Global Select
Back to all articles
Somewhat Bullish +45

Fifth Third Bancorp Has $3.06 Million Stake in Moderna, Inc. $MRNA

📈 Fifth Third Bancorp increased its MRNA stake by 157.5% in Q1, adding 36,912 shares to a total holding of 60,341 shares valued at $3.065 million.

🏦 Other institutions including MUFG Securities EMEA, Flagship Harbor Advisors, Cromwell Holdings, and EverSource Wealth Advisors established or increased new positions in the stock.

📉 Analyst consensus rating is 'Reduce' with a target price of $38.80, despite Goldman Sachs raising its target to $49.00 and Piper Sandler lifting its objective to $77.00.

💰 Insider selling activity was significant in the last three months, with executives offloading 125,088 shares worth approximately $6.19 million.

📊 Q1 revenue jumped 260.2% year-over-year to $389 million, significantly beating the consensus estimate of $236.37 million.

💸 The company reported a net loss of $3.40 per share for the quarter, missing analyst estimates by $0.38.

📈 Stock price opened at $59.49, trading above its 50-day moving average of $58.00 and 200-day moving average of $51.15.

🏢 Institutional investors own 75.33% of the outstanding shares, while corporate insiders hold 10.80%.

Bullish Signals
  • Moderna reported first-quarter revenue of $389 million, which was a 260.2% increase compared to the same quarter last year.
  • The company beat analyst consensus estimates for revenue by $152.63 million, reporting $389 million against an expected $236.37 million.
  • Goldman Sachs raised its price target on MRNA from $43.00 to $49.00 in a recent research report.
  • Piper Sandler lifted its price objective from $69.00 to $77.00 and assigned an 'overweight' rating to the stock.
  • Morgan Stanley increased its target price on MRNA from $33.00 to $39.00 in a report issued on July 8th.
  • Barclays raised its target price on Moderna from $25.00 to $48.00, indicating a higher valuation expectation.
  • Fifth Third Bancorp significantly grew its position by 157.5% in the first quarter, signaling strong institutional confidence.
  • The stock is trading above both its 50-day moving average ($58.00) and its 200-day moving average ($51.15).
Risk Factors
  • Moderna reported a loss of $3.40 per share for the quarter, missing analyst consensus estimates by $0.38.
  • Analyst consensus rating is 'Reduce' with a consensus target price of $38.80, which is below the current trading price.
  • Ten analysts have issued a Hold rating while five have given a Sell rating to the company's stock.
  • Insiders sold 125,088 shares worth approximately $6.19 million in the last three months, indicating reduced personal conviction.
  • Director Abbas Hussain sold 5,682 shares representing a 32.01% decrease in his ownership stake.
  • The stock has a PE ratio of -7.30, reflecting its current unprofitable status.
Full Analysis
Fifth Third Bancorp significantly increased its stake in Moderna, Inc. (MRNA) by 157.5% in the first quarter, purchasing an additional 36,912 shares to hold a total position of 60,341 shares valued at $3.065 million. Other institutional investors like MUFG Securities EMEA and Flagship Harbor Advisors also established new positions, while Cromwell Holdings and EverSource Wealth Advisors increased their holdings by nearly 40% and 148%, respectively. Institutional ownership of the stock stands at 75.33%. Analyst sentiment remains mixed with a consensus rating of 'Reduce' and a target price of $38.80, though recent reports show diverging views. Goldman Sachs raised its price target to $49.00 with a neutral rating, while Piper Sandler lifted its objective to $77.00 with an overweight rating. Conversely, Jefferies maintained a hold, and Barclays adjusted its target to $48.00 with an equal weight rating. Morgan Stanley also raised its target to $39.00. Insider trading activity reveals significant selling pressure as executives reduced their positions. Director Abbas Hussain sold 5,682 shares for approximately $265,000, and insider Shannon Thyme Klinger sold 3,471 shares for about $173,550 to cover tax obligations on vested equity. Collectively, insiders sold over 125,000 shares worth roughly $6.19 million in the last three months. Moderna reported first-quarter earnings of ($3.40) per share, missing analyst estimates of ($3.02), though revenue surged to $389 million, beating expectations of $236.37 million and representing a 260% year-over-year increase. The stock currently trades at $59.49 with a market cap of $23.61 billion, trading above its 50-day moving average but below its one-year high of $85.60.